Novo Nordisk
NVO
1,745 hedge funds and large institutions have $41.8B invested in Novo Nordisk in 2024 Q1 according to their latest regulatory filings, with 320 funds opening new positions, 729 increasing their positions, 484 reducing their positions, and 70 closing their positions.
357% more first-time investments, than exits
New positions opened: 320 | Existing positions closed: 70
51% more repeat investments, than reductions
Existing positions increased: 729 | Existing positions reduced: 484
25% more capital invested
Capital invested by funds: $33.4B → $41.8B (+$8.4B)
15% more funds holding
Funds holding: 1,512 → 1,745 (+233)
14% more funds holding in top 10
Funds holding in top 10: 70 → 80 (+10)
0.16% more ownership
Funds ownership: 9.31% → 9.47% (+0.16%)
10% less call options, than puts
Call options by funds: $1.01B | Put options by funds: $1.13B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$588M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$375M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$205M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$138M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.1B |
| 2 |
Renaissance Technologies
New York
|
-$365M |
| 3 |
BlackRock
New York
|
-$206M |
| 4 |
Jennison Associates
New York
|
-$172M |
| 5 |
SFM
Soros Fund Management
New York
|
-$90.1M |
NVO Hedge Fund Activity: Q1 2024 in Review
1,745 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2024, worth a combined $41.8B — up 25% from $33.4B a quarter earlier.
Buyers outnumbered sellers: 320 funds opened new NVO positions and 70 closed out — a net gain of 250 holders — while 729 added to existing stakes and 484 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $588M. The largest seller was Morgan Stanley, cutting an estimated $1.1B.
- 1,745 institutional investors held Novo Nordisk (NVO) as of Q1 2024, up from 1,512 in Q4 2023.
- Funds reported $41.8B of Novo Nordisk stock for Q1 2024, up 25% quarter-over-quarter.
- 320 funds opened new Novo Nordisk positions in Q1 2024 and 70 closed out, a net change of +250 holders.
- The largest Novo Nordisk buyer in Q1 2024 was Fidelity Investments, an estimated $588M added.
- The largest Novo Nordisk seller in Q1 2024 was Morgan Stanley, an estimated $1.1B sold.
Based on aggregated 13F filings for Q1 2024.